Clinical and operational value of the extensively drug-r

European Respiratory Journal
30, 623-626
DOI: 10.1183/09031936.00077307

Citation Report

#	Article	IF	Citations
2	Prognosis of XDR-TB among patients without HIV infection. FEMS Immunology and Medical Microbiology, 2008, 54, 155-156.	2.7	0
3	Advances in the diagnosis of tuberculosis. Respirology, 2008, 13, S73.	2.3	5
5	Economics of antibiotic resistance. Expert Review of Anti-Infective Therapy, 2008, 6, 523-539.	4.4	79
6	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	6.7	131
7	Effectiveness and Tolerance of Antituberculosis Treatment Regimens Without Isoniazid and Rifampicin: Analysis of 85 Cases. Archivos De Bronconeumologia, 2008, 44, 478-483.	0.8	5
8	Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Review of Anti-Infective Therapy, 2008, 6, 713-724.	4.4	37
9	Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet, The, 2008, 372, 1403-1409.	13.7	150
10	XDR tuberculosis can be cured with aggressive treatment. Lancet, The, 2008, 372, 1363-1365.	13.7	8
11	Comparative analysis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis â€“ Epidemiology and predictive factors. Revista Portuguesa De Pneumologia, 2008, 14, 829-842.	0.7	3
12	Treatment Outcomes for HIVâ€Uninfected Patients with Multidrugâ€Resistant and Extensively Drugâ€Resistant Tuberculosis. Clinical Infectious Diseases, 2008, 47, 496-502.	5.8	140
13	Extensively drug-resistant tuberculosis: is its definition correct?. European Respiratory Journal, 2008, 32, 1413-1415.	6.7	13
14	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	5.8	35
15	Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis. New England Journal of Medicine, 2008, 359, 563-574.	27.0	364
16	Extensively Drug-Resistant Tuberculosis in the United States, 1993-2007. JAMA - Journal of the American Medical Association, 2008, 300, 2153.	7.4	104
17	Drug Resistant Tuberculosis â€” Is There Hope?. Australasian Medical Journal, 2008, 1, 226-228.	0.1	0
18	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	6.7	67
19	Of Blind Men and Elephants: Making Sense of Extensively Drug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1000-1001.	5.6	16
20	Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. Emerging Infectious Diseases, 2008, 14, 1700-1706.	4.3	113

#	Article	IF	Citations
21	Emergence of Extensive Drug Resistance during Treatment for Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2008, 359, 2398-2400.	27.0	57
22	Facing Extensively Drug-Resistant Tuberculosis â€" A Hope and a Challenge. New England Journal of Medicine, 2008, 359, 636-638.	27.0	32
23	Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1075-1082.	5.6	157
25	Epidemiology and Treatment of Multidrug Resistant Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 499-524.	2.1	37
29	Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Current Opinion in Infectious Diseases, 2008, 21, 587-595.	3.1	136
30	Tuberculosis, one disease, many faces. Monaldi Archives for Chest Disease, 2008, 69, 2-4.	0.6	7
31	Diagnosis of Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis: Current Standards and Challenges. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 169-172.	1.9	56
32	Acquired Drug Resistance during Standardized Treatment with First-line Drugs in Patients with Multidrug-Resistant Tuberculosis. Tuberculosis and Respiratory Diseases, 2009, 66, 198.	1.8	1
33	Radiological Findings of Extensively Drug-Resistant Pulmonary Tuberculosis in Non-AIDS Adults: Comparisons with Findings of Multidrug-Resistant and Drug-Sensitive Tuberculosis. Korean Journal of Radiology, 2009, 10, 207.	3.4	50
34	Extensively Drug-resistant Tuberculosis(XDR-TB). Journal of Medicine (Bangladesh), 2009, 10, 97-99.	0.2	0
35	Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. European Respiratory Journal, 2009, 33, 1085-1094.	6.7	116
36	A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. European Respiratory Journal, 2009, 34, 387-393.	6.7	170
37	Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. European Respiratory Journal, 2009, 34, 180-183.	6.7	38
38	Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Review of Respiratory Medicine, 2009, 3, 245-254.	2.5	8
39	Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. European Respiratory Journal, 2009, 33, 581-585.	6.7	28
40	Multidrug- and extensively drug-resistant tuberculosis: an emerging threat. European Respiratory Review, 2009, 18, 195-197.	7.1	27
41	A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrobial Agents and Chemotherapy, 2009, 53, 3181-3189.	3.2	212
42	Steps forward in LRTI and tuberculosis: update from the ERS Respiratory Infections Assembly. European Respiratory Journal, 2009, 33, 1448-1453.	6.7	2

#	Article	IF	Citations
43	MDR-TB and XDR-TB: drug resistance and treatment outcomes. European Respiratory Journal, 2009, 34, 778-779.	6.7	30
44	Consensus Not Yet Reached on Key Drugs for Extensively Drugâ€Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	5.8	6
45	High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis, 2009, 89, 334-353.	1.9	251
46	A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. Expert Opinion on Medical Diagnostics, 2009, 3, 99-122.	1.6	7
47	Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2009, 4, e6914.	2.5	346
48	Extensively drug-resistant tuberculosis. Lancet Infectious Diseases, The, 2009, 9, 19-30.	9.1	200
49	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control. Clinics in Chest Medicine, 2009, 30, 637-665.	2.1	64
50	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	6.7	163
51	Predictors of Extensively Drug-Resistant Pulmonary Tuberculosis. Annals of Internal Medicine, 2009, 150, 766.	3.9	49
52	Computed Tomography Features of Extensively Drug-Resistant Pulmonary Tuberculosis in Non-HIV-Infected Patients. Journal of Computer Assisted Tomography, 2010, 34, 559-563.	0.9	20
53	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	2.6	18
54	Surgical Treatment for Multidrug-Resistant and Extensive Drug-Resistant Tuberculosis. Annals of Thoracic Surgery, 2010, 89, 1597-1602.	1.3	66
55	Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Tropical Medicine and International Health, 2010, 15, 1052-1066.	2.3	62
56	Drugâ€resistant tuberculosis: Past, present, future. Respirology, 2010, 15, 413-432.	2.3	110
57	Treatment Outcomes among Patients with Extensively Drugâ€Resistant Tuberculosis: Systematic Review and Metaâ€Analysis. Clinical Infectious Diseases, 2010, 51, 6-14.	5.8	235
58	Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. European Respiratory Journal, 2010, 36, 584-593.	6.7	72
59	HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 80-86.	5.6	273
60	Development of a standardised tool to survey MDR-/XDR-TB case management in Europe. European Respiratory Journal, 2010, 36, 208-211.	6.7	22

#	Article	IF	Citations
61	MODELLING THE SPREAD OF TUBERCULOSIS, INCLUDING DRUG RESISTANCE AND HIV: A CASE STUDY IN PAPUA NEW GUINEAâ€™S WESTERN PROVINCE. ANZIAM Journal, 2010, 52, 26-45.	0.2	8
62	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. Microbial Drug Resistance, 2010, 16, 81-86.	2.0	22
63	Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery. Pharmaceuticals, 2010, 3, 2268-2290.	3.8	47
64	Extensively drug-resistant tuberculosis: back to the future. European Respiratory Journal, 2010, 36, 475-477.	6.7	39
65	Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2010, 65, 1551-1561.	3.0	34
66	Treatment Outcomes and Survival Based on Drug Resistance Patterns in Multidrug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 113-119.	5.6	110
67	Two Pediatric Cases of Multidrug-Resistant Tuberculosis Treated With Linezolid and Moxifloxacin. Pediatrics, 2010, 126, e1253-e1256.	2.1	27
69	Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. International Journal of Infectious Diseases, 2010, 14, e399-e402.	3.3	16
70	Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet, The, 2010, 375, 1798-1807.	13.7	225
71	XDR tuberculosis in South Africa: old questions, new answers. Lancet, The, 2010, 375, 1760-1761.	13.7	8
72	Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infectious Diseases, The, 2010, 10, 621-629.	9.1	479
73	Management of multidrug-resistant tuberculosis: an update. Therapeutic Advances in Respiratory Disease, 2010, 4, 117-127.	2.6	23
74	Tuberculosis in Europe: a problem of drug resistance or much more?. Expert Review of Respiratory Medicine, 2010, 4, 189-200.	2.5	19
75	Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 180-185.	5.6	14
76	WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal, 2011, 38, 516-528.	6.7	718
78	Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. European Respiratory Journal, 2011, 37, 1269-1282.	6.7	116
79	Treatment of tuberculosis: update 2010. European Respiratory Journal, 2011, 37, 441-462.	6.7	92
80	Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. European Respiratory Journal, 2011, 38, 730-733.	6.7	47

#	Article	IF	Citations
81	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. European Respiratory Journal, 2011, 37, 1283-1285.	6.7	14
82	TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. European Respiratory Journal, 2011, 38, 1221-1223.	6.7	52
83	Update on tuberculosis: TB in the early 21st century. European Respiratory Review, 2011, 20, 71-84.	7.1	37
84	Tuberculosis: an ancient and evergreen disease. European Respiratory Review, 2011, 20, 69-70.	7.1	2
85	Impaired pulmonary function and the risk of tuberculosis: a population-based cohort study. European Respiratory Journal, 2011, 37, 1285-1287.	6.7	8
87	Is multidrug-resistant tuberculosis on the rise in Mozambique? Results of a national drug resistance survey. European Respiratory Journal, 2011, 38, 222-224.	6.7	25
88	Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: Clinical characteristics and treatment outcomes. Scandinavian Journal of Infectious Diseases, 2011, 43, 280-285.	1.5	18
89	Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis: a Systematic Review with Meta-Analyses. Antimicrobial Agents and Chemotherapy, 2011, 55, 4499-4505.	3.2	117
90	On linezolid efficacy and tolerability. European Respiratory Journal, 2012, 39, 770-772.	6.7	23
91	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
92	Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 5465-5475.	3.2	48
93	â€˜Z ^S -MDR-TBâ€™ versus â€˜Z ^R -MDR-TBâ€™: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerging Microbes and Infections, 2012, 1, 1-4.	6.5	42
94	Availability of anti-tuberculosis drugs in Europe: Table 1â€“. European Respiratory Journal, 2012, 40, 500-503.	6.7	9
95	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. Clinical Infectious Diseases, 2012, 54, 1379-1380.	5.8	67
96	Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. European Respiratory Journal, 2012, 39, 1425-1431.	6.7	135
97	Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002â€“2005. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1069-1074.	1.2	20
98	Pulmonary Resection for Extensively Drug Resistant Tuberculosis in Kwazulu-Natal, South Africa. Annals of Thoracic Surgery, 2012, 94, 381-386.	1.3	12
99	Multidrug and extensively drug-resistant tuberculosis in Lisbon and Vale do Tejo, Portugal, from 2008 to 2010. International Journal of Mycobacteriology, 2012, 1, 131-136.	0.6	9

#	Article	IF	Citations
100	TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged?. European Respiratory Journal, 2012, 39, 619-625.	6.7	74
101	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	6.7	188
103	Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. European Respiratory Journal, 2012, 40, 814-822.	6.7	58
104	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. European Respiratory Journal, 2012, 40, 1430-1442.	6.7	346
105	Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review. PLoS ONE, 2012, 7, e47370.	2.5	29
106	Tbnet â€" Collaborative research on tuberculosis in Europe. European Journal of Microbiology and Immunology, 2012, 2, 264-274.	2.8	15
107	Continuous positive airway pressure delivered by oronasal mask may not be effective for obstructive sleep apnoea: Figure 1â€“. European Respiratory Journal, 2012, 40, 503-505.	6.7	48
108	Management of difficult multidrugâ€resistant tuberculosis and extensively drugâ€resistant tuberculosis: Update 2012. Respirology, 2013, 18, 8-21.	2.3	54
109	Do we need a new Fleming Ã©poque: The nightmare of drug-resistant tuberculosis. International Journal of Mycobacteriology, 2013, 2, 123-125.	0.6	9
110	Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 299-307.	1.2	119
111	Multidrug-resistant tuberculosis. Brazilian Journal of Infectious Diseases, 2013, 17, 239-246.	0.6	16
112	Epidemiology of Multidrug Resistant Tuberculosis (MDR-TB). , 2013, , .		1
113	Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. International Journal of Antimicrobial Agents, 2013, 42, 36-41.	2.5	25
114	Characterisation of the flexibility of substrate binding loop in the binding of direct InhA inhibitors. International Journal of Computational Biology and Drug Design, 2013, 6, 318.	0.3	8
115	Management of Multidrug Resistant Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 044-059.	2.1	34
116	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	6.7	346
117	Tuberculosis: are we making it incurable?. European Respiratory Journal, 2013, 42, 5-8.	6.7	17
118	Impact of Diabetes on Treatment Outcomes and Long-Term Survival in Multidrug-Resistant Tuberculosis. Respiration, 2013, 86, 472-478.	2.6	45

#	Article	IF	Citations
119	WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4097-4104.	3.2	80
120	Yield of Contact Investigations in Households of Patients With Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2014, 58, 381-391.	5.8	114
121	Risk factors for extensively drugâ€resistant tuberculosis: a review. Clinical Respiratory Journal, 2014, 8, 11-23.	1.6	33
122	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respiratory Medicine,the, 2014, 2, 321-338.	10.7	237
123	The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nature Reviews Microbiology, 2014, 12, 159-167.	28.6	328
124	Epidemiology of Tuberculosis and the Rise of XDR-TB. Current Treatment Options in Infectious Diseases, 2014, 6, 353-376.	1.9	2
125	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	5.8	116
126	Extensively drug-resistant tuberculosis: epidemiology and management. Clinical Epidemiology, 2014, 6, 111.	3.0	98
127	<I>Mycobacterium tuberculosis</I> resistance in pulmonary TB patients in Cameroon: a phenotypic susceptibility assay. International Journal of Tuberculosis and Lung Disease, 2015, 19, 823-827.	1.2	1
128	Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1463-1471.	1.1	22
129	Phytochemical Analyses and Activity of Herbal Medicinal Plants of North- East India for Anti-Diabetic, Anti-Cancer and Anti-Tuberculosis and their Docking Studies. Current Topics in Medicinal Chemistry, 2015, 15, 21-36.	2.1	16
130	Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	4
131	Performance of REBA MTB-XDR to detect extensively drug-resistant tuberculosis in an intermediate-burden country. Journal of Infection and Chemotherapy, 2015, 21, 346-351.	1.7	8
132	Nanocarrier-based interventions for the management of MDR/XDR-TB. Journal of Drug Targeting, 2015, 23, 287-304.	4.4	11
133	Totally drugâ€resistant tuberculosis and adjunct therapies. Journal of Internal Medicine, 2015, 277, 388-405.	6.0	137
135	Facing multi-drug resistant tuberculosis. Pulmonary Pharmacology and Therapeutics, 2015, 32, 144-148.	2.6	28
137	Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia. The Malaysian Journal of Medical Sciences, 2016, 23, 17-25.	0.5	15
138	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	6.7	27

#	Article	IF	Citations
139	Mycobacterial (Skin) Infections. , 2016, , 81-139.		3
140	Antibiotic and Antifungal Therapies in Dermatology. , 2016, , .		0
141	Lobar Collapse Therapy Using Endobronchial Valves as a New Complementary Approach to Treat Cavities in Multidrug-Resistant Tuberculosis and Difficult-to-Treat Tuberculosis: A Case Series. Respiration, 2016, 92, 316-328.	2.6	18
142	Multidrug-resistant tuberculosis in Lithuania â€“ Still a long way ahead. Medicina (Lithuania), 2016, 52, 69-78.	2.0	2
143	Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2017, 65, 772-778.	5.8	12
144	Structure-Based Optimization of Pyridoxal 5â€²-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2017, 60, 5507-5520.	6.4	31
145	Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. International Journal of Infectious Diseases, 2017, 65, 8-14.	3.3	5
146	Bilateral cavitary multidrug- or extensively drug-resistant tuberculosis: role of surgeryâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 618-624.	1.4	12
147	Management of Multidrug-Resistant Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 310-324.	2.1	32
149	Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. European Respiratory Journal, 2019, 54, 1800353.	6.7	22
150	Long-term Follow-up Reveals High Posttreatment Mortality Rate Among Patients With Extensively Drug-Resistant Tuberculosis in the Country of Georgia. Open Forum Infectious Diseases, 2019, 6, ofz152.	0.9	10
152	The relationship between inflammatory markers extracted from complete blood count and active pulmonary tuberculosis. Reviews in Medical Microbiology, 2019, 30, 18-25.	0.9	1
153	Efflux pump as alternate mechanism for drug resistance in Mycobacterium tuberculosis. Indian Journal of Tuberculosis, 2019, 66, 20-25.	0.7	20
154	Recent updates on drug resistance in Mycobacterium tuberculosis. Journal of Applied Microbiology, 2020, 128, 1547-1567.	3.1	190
155	Synthesis and in vitro antitubercular activity of pyridine analouges against the resistant Mycobacterium tuberculosis. Bioorganic Chemistry, 2020, 102, 104099.	4.1	13
156	Survival of patients with multidrug-resistant tuberculosis in Central China: a retrospective cohort study. Epidemiology and Infection, 2020, 148, e50.	2.1	4
157	Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors. In Silico Pharmacology, 2021, 9, 23.	3.3	34
158	Risk Factors for MDR and XDR-TB in a Tertiary Referral Hospital in India. PLoS ONE, 2010, 5, e9527.	2.5	45

#	Article	IF	Citations
159	Extensively Drug-Resistant Tuberculosis (XDR-TB) - A Potential Threat in Ireland. Open Respiratory Medicine Journal, 2007, 1, 7-9.	0.4	2
160	Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007. Eurosurveillance, 2010, 15, .	7.0	24
161	Challenges and Controversies in Defining Totally Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2012, 18, e2-e2.	4.3	17
162	Drug Resistant Tuberculosis. Deutsches Ärzteblatt International, 2010, 107, 10-9.	0.9	45
163	Shortened tuberculosis treatment regimens: what is new?. Jornal Brasileiro De Pneumologia, 2020, 46, e20200009-e20200009.	0.7	21
164	The multidrug-resistant tuberculosis threat: old problems and new solutions. Journal of Thoracic Disease, 2015, 7, E354-60.	1.4	8
165	Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian Journal of Medical Research, 2017, 145, 271-293.	1.0	25
166	Rapid diagnosis of drug resistant tuberculosis: current perspectives and challenges. Indian Journal of Medical Specialities, 2012, 3, .	0.1	1
167	IN - VITRO EVALUATION OF SUSCEPTIBILITY OF M. TUBERCULOSIS TO SECOND LINE OF DRUGS. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 1836-1842.	0.0	0
168	Comparison of Sula Liquid Media and Conventional Method for Diagnosis of MDR-TB. Journal of Dhaka Medical College, 2017, 25, 100-104.	0.1	0
169	Most important epidemiological tuberculosis indicators in the beginning of the III Millennium. Vestnik of Russian Military Medical Academy, 2018, 20, 230-234.	0.3	0
170	Extensively Drug-resistant Tuberculosis (XDR-TB)-inhibitors to Overcome the Scourge of Drug-resistant Tuberculosis: a Perspective. Reviews and Advances in Chemistry, 2020, 10, 112-139.	0.5	1
171	Treatment options for MDR- and XDR-TB. , 0, , 232-244.		2
172	Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. International Journal of Tuberculosis and Lung Disease, 2010, 14, 1244-51.	1.2	17
173	Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review. Molecular Diversity, 2022, 26, 2949-2965.	3.9	5
175	Rapid Diagnosis of XDR and Pre-XDR TB: A Systematic Review of Available Tools. Archivos De Bronconeumologia, 2022, 58, 809-820.	0.8	4
176	Advances in Treatment of Drug-Resistant Pulmonary TB: What Is the Latest Approach to Treat Drug-Resistant Pulmonary TB?. Respiratory Disease Series, 2022, , 133-165.	0.0	0
177	Characterization of isoniazid incorporation into chitosan-poly(aspartic acid) nanoparticles. International Journal of Polymeric Materials and Polymeric Biomaterials, 0, , 1-10.	3.4	0

#	Article	IF	Citations
178	An update on ATP synthase inhibitors: A unique target for drug development in M. tuberculosis. Progress in Biophysics and Molecular Biology, 2023, 180-181, 87-104.	2.9	2
179	Extensively Drug-Resistant Tuberculosis. , 2023, , 121-134.		0